FDA Details National Vaccine Plan - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Details National Vaccine Plan


Dr. Karen Midthun, director of FDA’s Center for Biologics Evaluation and Research, outlined the importance of the Department of Health and Human Services (HHS) National Vaccine Plan, in a FDA blog on March 11, 2014. Midthun points out how crucial vaccines are in protecting public health and discusses FDA’s role in ensuring a stable supply of safe vaccines.

According to Midthun, the National Vaccine Plan plans on developing new vaccines, enhancing the vaccine safety system, supporting enhanced communication regarding vaccine decision-making, ensuring a stable supply of vaccines, and increasing global prevention of disease through vaccination. The National Vaccine Program Office recently issued the State of the National Vaccine Plan, which details the government’s progress regarding the vaccine plan. Some of the accomplishments listed in the report include the establishment of a new generation of influenza vaccines, new production techniques, and advances in electronic health data. Other accomplishments include the establishment of Vaccines.gov and vaccine promotional materials.

The report states that the National Vaccine Plan will continue in the coming years with more research into new vaccines, extension of monitoring systems, and continued development of communication paths. The report can be found on the HHS website.

Source: FDA.gov

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here